t
ImmuPharma PLC announced on 7 April 2026 that shareholders approved both resolutions at its General Meeting held earlier that day, with Resolution 1 receiving 91.46% 'For' votes and Resolution 2 receiving 88.91% 'For' votes. Following the meeting, the directors allotted 121,187,447 new ordinary shares, comprising 100,000,000 Subscription Shares, 12,000,000 Value Payment Shares, 7,812,447 WRAP Retail Offer Shares, and 1,375,000 Fee Shares. Application has been made for these new shares to be admitted to AIM, with admission expected at 8:00 a.m. on 8 April 2026, resulting in a total issued ordinary share capital of 623,911,379 Ordinary Shares.
| Date | 7 Apr 2026 |
| Time | 11:45:21 |
| Category | AGMs and other meetings |
| ID | 4894Z |
7 April 2026
ImmuPharma PLC
("ImmuPharma" or the "Company")
Result of General Meeting and TVR
Resolutions Approved
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that both resolutions proposed at the General meeting held earlier today were approved by Shareholders.
This is further to its Fundraising announcement published on 17 March 2026 at 7:00 a.m. (the "Fundraising RNS") and the WRAP Retail Offer announcement published on 17 March 2026 at 7:01 a.m. (the "WRAP RNS"),
Details of the voting are as set out below:
|
ORDINARY RESOLUTION |
For |
% For |
Against |
% Against |
Withheld |
|
1. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting |
77,375,610 |
91.46% |
7,228,476 |
8.54% |
1,056,465 |
|
SPECIAL RESOLUTION |
75,221,313 |
88.91% |
9,378,404 |
11.09% |
1,060,834 |
Allotment of Shares
At a Board meeting held following the General Meeting, 100,000,000 Subscription Shares, 12,000,000 Value Payment Shares, 7,812,447 WRAP Retail Offer Shares and 1,375,000 Fee Shares (together the "New Ordinary Shares") have been allotted.
Application has been made for the New Ordinary Shares to be admitted to trading on AIM ("Admission"), and Admission is expected to occur at 8.00 a.m. on 8 April 2026.
Total Voting Rights
Upon admission of the New Ordinary Shares, the Company's issued ordinary share capital will comprise 623,911,379 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. This figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
All New Ordinary Shares have been issued free of all liens, charges and encumbrances and will, from Admission, rank pari passu in all respects with the Company's existing Ordinary Shares.
Terms used but not defined in this announcement have the same meaning as set out in the Fundraising RNS and / or WRAP RNS.
For further information, please contact:
|
ImmuPharma PLC (www.immupharma.co.uk) Tim McCarthy, Chief Executive Officer Lisa Baderoon, Head of Investor Relations
|
+44 (0) 207 206 2650
+ 44 (0) 7721 413496 |
|
SPARK Advisory Partners Limited (NOMAD) Neil Baldwin
|
+44 (0) 203 368 3550 |
|
Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney
|
44 (0) 20 3650 3650
|
|
SI Capital (Joint Broker) Nick Emerson
|
+44 (0) 1483 413500 |
|
|
|
For additional information about ImmuPharma please visit www.immupharma.co.uk.
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.